Search - tctmd.com

Displaying 341 - 360 of 509

Sort: Relevancy | Date

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Todd Neale

August 17, 2015

News Daily News

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

Todd Neale

August 17, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

Presentation

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Presenter: BM. Everett BM

August 14, 2015

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

Presentation

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

Presenter: D. Gaudet

August 12, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Yael L. Maxwell

August 12, 2015

Presentation

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

Presenter: Vera Bittner

August 11, 2015

Presentation

EES vs CABG for Patients With Diabetes and Multivessel Disease

Presenter: Sripal Bangalore

July 30, 2015

Presentation

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

Presenter: Mohamed Abdel-Wahab

July 23, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Conference News EuroPCR 2015

Evolving DES Technology May Benefit Diabetic Patients

Caitlin E. Cox

May 19, 2015

Advertisement

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

EES vs CABG for Patients With Diabetes and Multivessel Disease

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Evolving DES Technology May Benefit Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content